Financial PerformanceCeribell has reported full-year gross margins of approximately 87% and total revenue of $65.4 million, representing a 45% year-over-year growth.
Market ExpansionThe company's pipeline includes initiatives like recent label expansion into pediatrics and plans for extension into neonates and new indications, which are expected to expand its Total Addressable Market.
Revenue GrowthCeribell's sales of $20.5 million surpassed estimates, driven by new account acquisitions and strong utilization in existing accounts.